Phase 3RecruitingPriority 1 · Highest priorityNCT06072131
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Plain-language summary
This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 11 US locations across multiple states.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Belinostat Injection (DRUG): Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle | Pralatrexate Injection (DRUG): Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle | CHOP (DRUG): CHOP is the comparator arm | COP (DRUG): COP is given in combination with Pralatrexate
- Drugs / treatments
- Belinostat Injection, Pralatrexate Injection, CHOP, COP
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details